Kiniksa is committed to developing innovative medicines to treat diseases with significant unmet medical need. Clinical trials—research studies conducted voluntarily by human participants—test potential treatments for safety, efficacy, dosing, and potential side effects. This process helps researchers learn more about a disease and its diagnosis so they can determine potential ways to treat or prevent a disease. Regulatory authorities use trial data and other information to decide if a new product should be approved for commercial use. If you or someone you care for are looking for information about our clinical trials, please review our ongoing studies below.
Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis
Description: A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects With Prurigo Nodularis
Condition or Disease: Prurigo Nodularis, Pruritis
Phase: Phase 2
Summary: Measure percent change from baseline in Worst Itch Numeric Rating Scale.
Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation
Description: A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Mavrilimumab (KPL-301) Treatment in Adult Subjects Hospitalized With Severe COVID-19 Pneumonia and Hyper-inflammation
Condition or Disease: COVID
Phase: Phase 2/3
Summary: Interventional, randomized, double-blind, placebo-controlled study encompassing 2 development phases.